[Edaily Reporter Kwon Oh Seok ] PeopleBio, Inc.(304840)is accelerating its transformation into an “AI infrastructure company” by changing its corporate name and improving its financial structure.

PeopleBio, Inc. announced on the 3rd that it plans to hold an extraordinary general meeting of shareholders on the 20th to change its name to “TimeX AI” and to propose a 2-for-1 stock consolidation and a plan to cover accumulated losses using 79.2 billion won in capital surplus. The company plans to eliminate most of its accumulated losses to enhance financial soundness and lay the groundwork for future shareholder returns, including dividends. The name change also reflects the company’s commitment to clearly communicating to the outside world the shift toward an AI-centric business structure and presenting a new vision to the market.
The new name, “TimeX AI,” embodies the company’s commitment to pushing the boundaries of time to the “Extreme” in the AI industry, where competition is centered on speed measured in milliseconds, by leveraging data centers and semiconductors. To realize this vision, the company is focusing on three core business pillars: △ AI data center infrastructure and servers, △ semiconductors, and △ biotechnology.
In the AI infrastructure and server sector, the company is closely monitoring the expanding AI investments by major domestic semiconductor firms, such as SamsungElectronics’ plan to build an intelligent semiconductor factory that embeds AI throughout the entire process—from design to mass production—and SK hynix’s push for a 15GW-scale investment in large-scale data center infrastructure. The company explains that it is accelerating efforts to recruit personnel and identify new business opportunities to capitalize on related contract opportunities.
In the semiconductor sector, the company is currently engaged in several negotiations with SISTA, its joint venture partner for refurbished equipment, regarding the purchase and delivery of used 200mm wafer equipment to mid-sized domestic foundries, and is preparing to recognize revenue in the second half of the year.
The bio division is also proceeding in parallel by leveraging its existing strengths. After submitting an application for Breakthrough Device designation with the U.S. Food and Drug Administration (FDA), the company is making every effort to secure approval by August, including conducting additional on-site visits to assess its readiness. PeopleBio, Inc. stated, “With the extraordinary general meeting of shareholders as a turning point, we are accelerating our transformation into an AI infrastructure company,” adding, “We will achieve tangible results in our three core businesses—AI infrastructure and servers, semiconductors, and biotechnology—to expand our new growth foundation.”